This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Editorial

Funding, Conflicts, and Paradigms

Alan J. Gelenberg, MD

Published: May 15, 2005

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

This past February and March, the New York Times published an article (GardinerHarris and Alex Berenson, "10 Voters on Panel Backing Pain Pills Had Industry Ties,"Feb 25, 2005) and subsequent editorial (March 4) concerning an FDA Advisory Panel thatrecommended marketing of several COX-2 inhibitor analgesics. They cited the Center forScience in the Public Interest, an advocacy group, which found that 10 of the 37 panel membershad consulted for or received research support from manufacturers of the drugs beingreviewed. The Times then observed that, had the votes of the 10 scientists with industry connectionsbeen excluded, the panel would have voted to withdraw one of the drugs and recommendedblocking the return of another.’ ‹’ ‹


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 66

Quick Links: Assessment Methods , Research Methods Statistics

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...